Johnson & Johnson (JNJ): FY25 Q1 earnings call, Apr 15, 2025
No Kalshi or Polymarket word markets were listed for Johnson & Johnson’s Apr 15, 2025 earnings call (FY25 Q1). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
10 matches for “Procedure”; 5 quoted, at least 25 words apart.
…surgery, we recently announced we have started OTAVA clinical trials with a procedure that supports submission for US FDA de novo in general surgery with…
…and competitive PSA ablation catheter pressure. This was mostly offset by global procedure growth, new product uptake, and commercial execution. Abiomed delivered growth of 14%…
…newly launched products as the year progresses. Regarding MedTech, we expect normalized procedure volume and seasonality, and of course, we anniversary the Shockwave acquisition at…
…who may have benefits and coverage for prescription medications as well as procedures inclusive of elective procedures. We have seen in times past when there's…
…solid, and we feel good about the rest of the year regarding procedures and use of pharmaceuticals. I don't know any comments on that team?…
Agents: this page as TSV at /api/v1/appearances/johnson-and-johnson:2025-04-15:earnings_call · words: /api/v1/brief?appearance=johnson-and-johnson:2025-04-15:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP